Group 1 - The stock price of Jinshi Asia Pharmaceutical has decreased by 2.09% to 10.78 CNY per share as of October 28, with a total market capitalization of 4.33 billion CNY [1] - The company has seen a net outflow of 7.54 million CNY in main funds, with significant selling activity amounting to 2.52 million CNY from large orders [1] - Year-to-date, the stock price has increased by 31.77%, but it has experienced a decline of 5.36% over the last five trading days [1] Group 2 - Jinshi Asia Pharmaceutical, established on July 15, 2004, specializes in the research, production, and sales of pharmaceuticals and health foods, with 82.76% of its revenue coming from drug sales [2] - As of September 30, the company reported a revenue of 708 million CNY for the first nine months of 2025, a decrease of 6.37% year-on-year, while net profit increased by 66.47% to 96.77 million CNY [2] - The company has a total of 23,200 shareholders, reflecting a 1.72% increase from the previous period [2] Group 3 - Since its A-share listing, Jinshi Asia Pharmaceutical has distributed a total of 170 million CNY in dividends, with 71.91 million CNY paid out in the last three years [3]

Macro Highlights - The main goals for the "14th Five-Year Plan" period include significant achievements in high-quality development, substantial improvement in technological self-reliance, breakthroughs in comprehensive reforms, enhanced social civilization, improved quality of life, major progress in building a beautiful China, and a more solid national security barrier [1] - By 2035, the aim is to significantly elevate China's economic, technological, defense, and comprehensive national strength, with per capita GDP reaching the level of moderately developed countries, leading to a happier and better life for the people and basic realization of socialist modernization [1] Trade Relations - The Ministry of Commerce announced that a Chinese delegation led by Vice Premier He Lifeng will engage in economic and trade consultations with the U.S. in Malaysia from October 24 to 27, focusing on important issues in Sino-U.S. economic relations [1] EU Sanctions Response - The Ministry of Commerce expressed strong dissatisfaction and firm opposition to the EU's decision to sanction Chinese companies, including large oil refineries and traders, during the 19th round of sanctions against Russia, emphasizing the need to protect the legitimate rights and interests of Chinese enterprises [2] State-Owned Enterprises Planning - The State-owned Assets Supervision and Administration Commission held a meeting to discuss the "14th Five-Year Plan" for central enterprises, emphasizing the need to align with the strategic mission assigned by the Party Central Committee and to enhance core functions and competitiveness [3] - The meeting highlighted the importance of optimizing layout and structural adjustments in line with national needs and industry trends, and improving the quality of planning through thorough research and unified thinking [3] Foreign Exchange Management - The Deputy Director of the State Administration of Foreign Exchange encouraged the implementation of innovative and integrated exploratory policies in Shanghai, focusing on the use of AI and big data to enhance foreign exchange services [4] - The aim is to improve the cross-border financial service capabilities of Shanghai while balancing financial openness and security [4] Company News - Huagong Technology reported a 40.92% year-on-year increase in net profit for the first three quarters and is planning to issue H-shares for listing in Hong Kong [8] - Yangjie Technology terminated its acquisition of 100% equity in Better Electronics [8] - Xinda Securities received approval for the issuance of up to 10 billion yuan in technology innovation corporate bonds [8] - Shuangliang Energy plans to raise no more than 1.292 billion yuan for projects related to zero-carbon intelligent manufacturing [8] - New Lai Materials' subsidiary plans to invest 2 billion yuan in semiconductor core component projects [8] - Chuanfa Longmang's subsidiary intends to invest 366 million yuan in a 100,000 tons/year lithium dihydrogen phosphate project [8] - Steel Research High-tech plans to establish a subsidiary and new industrial base in Saudi Arabia [8] - Aote Electronics intends to terminate the smart integration project for intelligent outlets [8] - Shengyi Electronics expects a year-on-year net profit increase of 476% to 519% for the first three quarters [8] - Other companies reported significant year-on-year net profit growth, including Tianeng Heavy Industry (1359.03%), Te Yi Pharmaceutical (985.18%), and Zhuanlei Technology (598.09%) [8][9]

Core Insights - The company Jinshi Yao reported a revenue of 216,791,709.92 yuan for the third quarter of 2025, indicating a significant growth in financial performance [2] - The net profit attributable to shareholders reached 31,020,527.86 yuan, reflecting a year-on-year increase of 63.90% [2] Financial Performance - Revenue for Q3 2025: 216.79 million yuan [2] - Net profit for Q3 2025: 31.02 million yuan [2] - Year-on-year net profit growth: 63.90% [2]

Core Insights - The company reported a revenue of 707 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 6.37% [1] - The net profit attributable to shareholders increased to 96.77 million yuan, showing a significant year-on-year growth of 66.47% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 79.01 million yuan, reflecting a year-on-year increase of 51.82% [1] - The basic earnings per share stood at 0.24 yuan [1]

Core Viewpoint - Jinshi Yiyao (300434.SZ) reported a decline in operating revenue for Q3 2025, while net profit showed significant growth, indicating a mixed financial performance [1] Financial Performance - Operating revenue for Q3 2025 was 217 million yuan, a year-on-year decrease of 7.64% [1] - Net profit attributable to shareholders was 31.02 million yuan, reflecting a year-on-year increase of 63.90% [1] - Net profit attributable to shareholders after deducting non-recurring gains and losses was 23.29 million yuan, up 55.20% year-on-year [1]

Group 1 - The core point of the article is that Jinshi Yiyao (SZ 300434) announced its third-quarter report for 2025 during a board meeting held on October 22, 2025, in Hangzhou, Zhejiang [1] - For the first half of 2025, the revenue composition of Jinshi Yiyao is as follows: 82.76% from the pharmaceutical manufacturing industry, 14.09% from the machinery manufacturing industry, and 3.16% from real estate leasing and management [1] - As of the report, Jinshi Yiyao has a market capitalization of 4.6 billion yuan [1]

Core Viewpoint - Jinshiyao Pharmaceutical (300434) reported a decline in revenue for Q3 2025, while showing significant growth in net profit [1] Financial Performance - In Q3 2025, the company achieved revenue of 217 million yuan, a year-on-year decrease of 7.64% [1] - The net profit attributable to shareholders for Q3 2025 was 31.02 million yuan, reflecting a year-on-year increase of 63.90% [1] - For the first three quarters of 2025, the company reported total revenue of 708 million yuan, down 6.37% year-on-year [1] - The net profit attributable to shareholders for the first three quarters was 96.77 million yuan, marking a year-on-year increase of 66.47% [1]

证券代码：300434 证券简称：金石亚药 公告编号：2025-040 四川金石亚洲医药股份有限公司 本议案已经公司董事会审计委员会审核通过。 表决结果：11 票同意，0 票反对，0 票弃权，本议案获得通过。 三、备查文件 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 四川金石亚洲医药股份有限公司（以下简称"公司"）第五届董事会第十一 次会议于 2025 年 10 月 22 日在浙江杭州亚科中心公司会议室以现场结合通讯表 决方式召开。本次董事会会议通知已于 2025 年 10 月 17 日以电子邮件或网络方 式发出。会议应出席董事 11 名，实际出席董事 11 名；其中，董事郑志勇先生和 独立董事钟鹏先生、赵小微女士以通讯表决方式出席本次会议。本次会议由董事 长马益平先生主持。公司全体高级管理人员列席了本次会议。本次会议的召集、 召开程序符合《公司法》及《公司章程》的有关规定，会议表决合法有效。 二、董事会会议审议情况 经研究讨论，会议达成如下决议： 1、审议通过《2025 年第三季度报告》 具体内容详见同日刊登在巨潮资讯网（www. ...

四川金石亚洲医药股份有限公司 2025 年第三季度报告 证券代码：300434 证券简称：金石亚药 公告编号：2025-041 四川金石亚洲医药股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担 个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 1 四川金石亚洲医药股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 期增减 | | 比上年同期增减 | | 营业收入（元） | 216,791,709.92 | -7.64% ...

Market Overview - The chemical pharmaceutical sector increased by 0.82% on the previous trading day, with Jinshi Yao leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Top Gainers in Chemical Pharmaceutical Sector - Jinshi Yao (300434) closed at 11.39, up 11.78% with a trading volume of 640,000 shares and a turnover of 714 million yuan [1] - Guangji Pharmaceutical (000952) closed at 7.06, up 9.97% with a trading volume of 215,600 shares and a turnover of 150 million yuan [1] - New Ganjing (920367) closed at 23.21, up 9.02% with a trading volume of less than 37,000 shares and a turnover of 85.7 million yuan [1] - Lingkang Pharmaceutical (603669) closed at 5.97, up 7.37% with a trading volume of 327,700 shares and a turnover of 192 million yuan [1] - Xiangdi Pharmaceutical (301211) closed at 13.12, up 6.84% with a trading volume of 190,800 shares and a turnover of 249 million yuan [1] Top Losers in Chemical Pharmaceutical Sector - Anglikang (002940) closed at 38.92, down 6.58% with a trading volume of 210,700 shares and a turnover of 829 million yuan [2] - Shutaishen (300204) closed at 36.99, down 5.57% with a trading volume of 394,900 shares and a turnover of 1467 million yuan [2] - Yatai Pharmaceutical (002370) closed at 7.00, down 4.76% with a trading volume of 1,532,900 shares and a turnover of 1061 million yuan [2] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 421 million yuan from institutional investors and 643 million yuan from speculative funds, while retail investors saw a net inflow of 1.063 billion yuan [2][3] - Jinshi Yao (300434) had a net inflow of 98.99 million yuan from institutional investors, while retail investors had a net outflow of 71.82 million yuan [3] - Guangji Pharmaceutical (000952) saw a net inflow of 39.50 million yuan from institutional investors, but a net outflow of 23.01 million yuan from retail investors [3]